GlassScriptPhysician profile
Ravneet Thind
NPI 1215146378
$10,500.57
in general payments reported to CMS, 2019-2025
54 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $526 · 2021: $664 · 2022: $1,258 · 2023: $4,638 · 2024: $1,906 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,223 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,223.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Education | $131.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,500.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $882.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $790.03 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $686.91 | 2019-2025 | Lumakras, Xgeva, Vectibix |
| Janssen Biotech, INC. | $623.60 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| Mayne Pharma Commercial LLC | $408.91 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $397.78 | 2020-2025 | Opdivo, Opdualag |
| Pfizer INC. | $381.30 | 2021-2025 | |
| Astellas Pharma US INC | $258.29 | 2019-2024 | Xtandi, Padcev |
| Regeneron Healthcare Solutions, INC. | $232.52 | 2020-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $231.03 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Genmab U.S., INC. | $201.23 | 2023-2025 | Tivdak, Epkinly |
| Aveo Pharmaceuticals, INC. | $200.24 | 2021-2025 | Fotivda |
| Stemline Therapeutics INC. | $188.30 | 2023-2025 | Orserdu |
| Gilead Sciences, INC. | $184.53 | 2022-2025 | Trodelvy |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $167.75 | 2019-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $148.58 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $135.16 | 2020-2024 | Tagrisso |
| Genzyme Corporation | $124.03 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $118.57 | 2021-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $117.47 | 2022-2024 | Mektovi, Braftovi, Xalkori |
| Jazz Pharmaceuticals INC. | $112.30 | 2021-2024 | |
| Eisai INC. | $103.23 | 2023-2025 | |
| Daiichi Sankyo INC. | $97.73 | 2020-2025 | Enhertu, Datroway |
| Abbvie INC. | $96.94 | 2024-2025 | |
| Glaxosmithkline, LLC. | $95.29 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Seagen INC. | $89.34 | 2020-2023 | Tukysa |
| Taiho Oncology, INC. | $65.75 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.45 | 2020-2021 | |
| Exelixis INC. | $63.82 | 2023 | Cabometyx |
| Genentech USA, INC. | $61.01 | 2021-2024 | Venclexta, Polivy, Tecentriq |
| Puma Biotechnology, INC. | $56.41 | 2020-2025 | |
| Kyowa Kirin, INC. | $50.08 | 2022-2025 | Poteligeo |
| Coherus Oncology, INC. | $46.23 | 2020-2024 | |
| Pharmacosmos Therapeutics INC. | $40.90 | 2021 | |
| Rigel Pharmaceuticals, INC. | $40.81 | 2022-2023 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $38.63 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.28 | 2022-2025 | |
| Beigene USA, INC. | $32.65 | 2024 | Brukinsa |
| Tg Therapeutics, INC. | $32.60 | 2021 | |
| Kite Pharma, INC. | $30.50 | 2021-2025 | Yescarta |
| Tempus Ai, INC | $28.09 | 2024 | |
| Emd Serono, INC. | $26.80 | 2020-2022 | |
| Karyopharm Therapeutics INC. | $24.93 | 2022 | |
| Incyte Corporation | $21.31 | 2024 | Pemazyre, Monjuvi |
| Argenx US, INC. | $21.23 | 2024 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $20.94 | 2022 | |
| Novocure INC. | $19.51 | 2023 | Optune |
| Takeda Pharmaceuticals U.S.A., INC. | $19.21 | 2022 | |
| Adaptive Biotechnologies Corporation | $18.75 | 2022 | |
| Foundation Medicine, INC. | $17.55 | 2023 | |
| Mirati Therapeutics, INC. | $17.22 | 2023 | Krazati |
| Nestle Healthcare Nutrition INC. | $15.90 | 2020 | |
| Clovis Oncology, INC. | $15.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravneet Thind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.